Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma - Wikidata - awgldk - TriplyDB

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

http://www.wikidata.org/entity/Q33726989

about

Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.Romidepsin: in the treatment of T-cell lymphoma.Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer Histone deacetylase inhibitors: emerging mechanisms of resistance.Romidepsin in the treatment of cutaneous T-cell lymphoma.Histone deacetylase inhibitors: clinical implications for hematological malignancies.Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.Phase I trial of a new schedule of romidepsin in patients with advanced cancers.Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.Romidepsin: a novel histone deacetylase inhibitor for cancer.HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.Toxicological and metabolic considerations for histone deacetylase inhibitors.Romidepsin for peripheral T-cell lymphoma.Romidepsin for the treatment of non-Hodgkin's lymphoma.Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.Therapeutic Options for Aggressive T-Cell Lymphomas.The discovery and development of romidepsin for the treatment of T-cell lymphoma.Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).Romidepsin for cutaneous T-cell lymphoma.The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.

P2860

Q26771812-FC459E2A-6257-4C7A-B39B-2452A6720ACA Q30936712-0FAF88E3-84E2-461B-9AD4-781A154BA082 Q33390876-8AE43CD1-D059-4F6F-9B96-EFF14DE7DAD3 Q33394324-6F18C874-D3B7-4D48-8256-0054A1A9E60A Q33396519-83091B84-CD99-4542-94B1-0B9E2DAF42BA Q33405882-63F61DC7-7C70-40D6-9846-86B3CBD676CB Q33443153-216A7B21-43D6-4A3E-8DA5-ECAD50300918 Q34414452-C7ED9A25-EF6D-4D4E-A766-5D2E3FE5A4BE Q34683488-3D34768E-BF91-4CEE-A787-CF7446D433C4 Q34729026-D1981AA6-E7CB-4201-AE87-9DD91E395C34 Q35186682-491715DB-CA4F-4569-A814-B63C46251115 Q35557022-2FC4FCAA-3AAC-4D26-8412-D6C5EC59AEF2 Q35592607-3553327F-9B5E-41B8-B542-0360239496F9 Q35683831-F5849FFC-0AB6-4C91-B382-5E43DC2629C8 Q36001847-0F54A16B-7614-4C83-BFCB-B71F1374CB69 Q36283075-0A918A34-D343-4FE1-823F-3141339F9065 Q36301182-795512C3-8589-4191-B5ED-8184E0BE62D3 Q36850845-1E844D6F-7E6A-4B8C-AC66-E62CFEB8CBFE Q36923104-55C53685-B3BD-47E5-AA1A-08317FE40420 Q37667088-DA455A17-1502-4889-A279-CFCD92A1F47E Q37774667-DAE6C84F-848D-4E9B-A0A0-615A7ED104AA Q37893664-B44312FF-65FA-4925-BC98-6104504AE81B Q37993586-AD55F309-A762-4FCD-9B97-56B00AC12EAA Q38042561-1C1C23B8-1E71-4E63-8CAB-AC6FDCCDE8ED Q38071321-3D6C3D78-E73A-465E-A3DB-D55152CE8EDA Q38132813-E7C2F7CF-E176-43DF-A877-215B5B5821EE Q38455740-1B5AF415-8C8F-4BE7-A670-C9D6C03B9A7E Q38542620-EDA8F7FE-4080-4911-9726-D63C6AA95062 Q38595978-D90F4CEB-210C-4CCA-B703-859820EFEED3 Q38675843-1F791621-44CD-4CAF-AA76-7630DD51D4F3 Q38713744-9DD19C13-5AFF-4754-8AEB-20F8649412D4 Q38974433-9D58AAE6-FC9D-4966-BDC4-79C7662BFBE0 Q39062353-F705718D-287B-4CCF-B245-6EFB24ECDE35 Q39248784-62797E71-CDCF-41CF-B1CB-FAD0ADC1A500 Q39303355-982D9A4A-5144-498E-8F66-2FC3549E0DA3 Q40715942-A4906C6A-3B86-443A-9B07-2056620D6DE4 Q45716342-B6571817-438A-4842-B290-5C08145314A6

P2860

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

http://www.wikidata.org/entity/Q33726989

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Laboratory correlates for a ph ...... and peripheral T-cell lymphoma

@ast

Laboratory correlates for a ph ...... and peripheral T-cell lymphoma

@en

type

label

Laboratory correlates for a ph ...... and peripheral T-cell lymphoma

@ast

Laboratory correlates for a ph ...... and peripheral T-cell lymphoma

@en

prefLabel

Laboratory correlates for a ph ...... and peripheral T-cell lymphoma

@ast

Laboratory correlates for a ph ...... and peripheral T-cell lymphoma

@en

P1433

Q33726989-B57A45B5-ADEC-4A37-B140-51E114CBD1F0

P1476

Q33726989-2398B323-DC88-4632-942C-E36BDA26AF1F

P2093

Q33726989-0DE44B69-FD5A-4DA1-96CA-2116333A3634

Q33726989-2DCCF132-A8B3-4EC8-90EE-F1D2971D6208

Q33726989-30EF1EC2-166F-4EC9-8C3C-AC5A6334DE76

Q33726989-32E8EE29-9E0F-4AC7-87EC-58B51EC9972E

Q33726989-3524D08F-E3B9-4050-8D53-0A5EDD7F765E

Q33726989-4110EA7D-64D9-4211-AF32-394C54E88D4A

Q33726989-5D98A1E7-5459-4911-B295-A2B3EC98B6EA

Q33726989-80B56EF2-C176-40BC-A5F8-24E64E384E1B

Q33726989-83F93273-655A-4CD0-9EC1-038E9FF64202

Q33726989-8CFED8A4-FDC0-4B35-93AD-289C120A9D74

P2860

Q33726989-06DC8CA6-CC90-4F8E-A7A1-853E64EAFB07

Q33726989-0A8142E2-5172-4F36-8D46-20CD405FD5DD

Q33726989-0E99B45C-AFF0-417E-8BA2-B8F2A4A12ECC

Q33726989-0F653299-7817-433C-A737-BD6DD86B71F2

Q33726989-10DA41EA-E386-45A5-996E-02F85AF73792

Q33726989-12046055-E00E-4676-9330-2EDC95F39BCB

Q33726989-12FFB6D7-47C7-4BEF-ABF2-ECEC6ABF862C

Q33726989-1368B4B9-3F52-416D-B76B-0EB6FCF1046B

Q33726989-150DBEC2-5DE1-4EC5-8191-35A4D25C7483

Q33726989-1AECC1A8-88C1-4201-8825-61D701EC741E

P304

Q33726989-71E06D21-C032-41C8-9FB5-37FC4B9F539E

P31

Q33726989-4105F96C-8BF9-4168-8A7A-D53694737B97

P356

Q33726989-FCA10D97-023D-4847-9B50-6836E0A6B6A7

P407

Q33726989-707D05BE-C3F8-4608-ABA2-4FF8B01A12EA

P433

Q33726989-1C4F867E-673E-4A7F-BD0B-778EBB113603

P478

Q33726989-471B5688-F87D-4BB4-8F73-E86087161A87

P50

Q33726989-4DD51743-BCC8-45D4-9FAB-E52710E67B78

Q33726989-6456A106-9311-4497-9EE5-594D4D924158

P577

Q33726989-EE26FB43-8ADF-48CE-8EAE-4046C917C403

P5875

Q33726989-CE7B36FE-10F6-41A7-96DE-15707BF78928

P698

Q33726989-CC779064-96A5-4B64-9874-E12DD1253605

P921

Q33726989-AC063700-B5EE-426C-8D24-5FA054999D6E

P932

Q33726989-8076B3B7-2F50-4F96-BC9A-65E5607B2F22

P356

J.1365-2141.2009.07954.X

P1433

British Journal of Haematology

P1476

Laboratory correlates for a ph ...... and peripheral T-cell lymphoma

@en

P2093

Alex Ling

http://www.w3.org/2001/XMLSchema#string

Erin R Gardner

http://www.w3.org/2001/XMLSchema#string

Kenneth Steadman

http://www.w3.org/2001/XMLSchema#string

Maria Turner

http://www.w3.org/2001/XMLSchema#string

Richard L Piekarz

http://www.w3.org/2001/XMLSchema#string

Robin Frye

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

Susan E Bates

http://www.w3.org/2001/XMLSchema#string

Tito Fojo

http://www.w3.org/2001/XMLSchema#string

Tomasz Obrzut

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Induction of MAGE-3 expression in lung and esophageal cancer cells.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y.

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

P304

256-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07954.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth Kin Wah To

P577

2009-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38052826

http://www.w3.org/2001/XMLSchema#string

P698

19874311

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2838427

http://www.w3.org/2001/XMLSchema#string